Search

Your search keyword '"Chen, Shinn-Chern"' showing total 27 results
Start Over Author "Chen, Shinn-Chern" Search Limiters Full Text
27 results on '"Chen, Shinn-Chern"'

1. Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuan, a hyperendemic area of southern Taiwan

Author

Tsai, Pei‐Chien, primary, Dai, Chia‐Yen, additional, Huang, Ching‐I, additional, Yeh, Ming‐Lun, additional, Huang, Chung‐Feng, additional, Hsieh, Meng‐Hsuan, additional, Yang, Jeng‐Fu, additional, Hsu, Po‐Yao, additional, Liang, Po‐Cheng, additional, Lin, Yi‐Hung, additional, Jang, Tyng‐Yuan, additional, Hsieh, Ming‐Yen, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Chern, additional, Huang, Jee‐Fu, additional, Yu, Ming‐Lung, additional, Chuang, Wan‐Long, additional, and Chang, Wen‐Yu, additional

Published
2022
Full Text
View/download PDF

5. Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan

Author

Tsai, Pei-Chien, primary, Huang, Ching-I, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Hsu, Po-Yao, additional, Liang, Po-Cheng, additional, Lin, Yi-Hung, additional, Jang, Tyng Yuan, additional, Hsieh, Ming-Yen, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Chuang, Wan-Long, additional, and Chang, Wen-Yu, additional

Published
2021
Full Text
View/download PDF

7. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy

Author

Yeh, Ming‐Lun, primary, Kuo, Hsing‐Tao, additional, Huang, Ching‐I, additional, Huang, Chung‐Feng, additional, Hsieh, Ming‐Yen, additional, Liang, Po‐Cheng, additional, Lin, I‐Hung, additional, Hsieh, Meng‐Hsuan, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Chern, additional, Dai, Chia‐Yen, additional, Huang, Jee‐Fu, additional, Yu, Ming‐Lung, additional, and Chuang, Wan‐Long, additional

Published
2020
Full Text
View/download PDF

8. Viral Interference Between Dengue Virus and Hepatitis C Virus Infections

Author

Liang, Po-Cheng, primary, Chen, Kuan-Yu, additional, Huang, Chung-Hao, additional, Chang, Ko, additional, Lu, Po-Liang, additional, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Huang, Ching-I, additional, Hsieh, Meng-Hsuan, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Chuang, Wan-Long, additional, Chen, Yen-Hsu, additional, Huang, Jee-Fu, additional, and Yu, Ming-Lung, additional

Published
2020
Full Text
View/download PDF

10. Wisteria floribunda agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients

Author

Yeh, Ming-Lun, primary, Huang, Chung-Feng, additional, Huang, Ching-I, additional, Dai, Chia-Yen, additional, Lin, I-Hung, additional, Liang, Po-Cheng, additional, Hsieh, Meng-Hsuan, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Huang, Jee-Fu, additional, Chen, Jyh-Jou, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2019
Full Text
View/download PDF

11. The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

Author

Yeh, Ming‐Lun, primary, Huang, Chung‐Feng, additional, Huang, Ching‐I, additional, Hsieh, Ming‐Yen, additional, Hou, Nei‐Jen, additional, Lin, I‐Hung, additional, Liang, Po‐Cheng, additional, Tsai, Yi‐Shan, additional, Hsieh, Meng‐Hsuan, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Chern, additional, Dai, Chia‐Yen, additional, Huang, Jee‐Fu, additional, Yu, Ming‐Lung, additional, and Chuang, Wan‐Long, additional

Published
2019
Full Text
View/download PDF

12. Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy.

Author

Yeh, Ming‐Lun, Kuo, Hsing‐Tao, Huang, Ching‐I, Huang, Chung‐Feng, Hsieh, Ming‐Yen, Liang, Po‐Cheng, Lin, I‐Hung, Hsieh, Meng‐Hsuan, Lin, Zu‐Yau, Chen, Shinn‐Chern, Dai, Chia‐Yen, Huang, Jee‐Fu, Yu, Ming‐Lung, and Chuang, Wan‐Long

Subjects
HEPATITIS C virus, HEPATOCELLULAR carcinoma, LIFE expectancy, SURVIVAL analysis (Biometry), PROGRESSION-free survival
Abstract

Whether patients with advanced hepatocellular carcinoma (aHCC) benefit from hepatitis C virus (HCV) eradication is uncertain. We aimed to investigate whether a survival benefit was conferred by HCV eradication in aHCC patients. This retrospective cohort study enrolled 168 HCV‐infected aHCC patients from April 2013 to January 2019. All patients were treated with sorafenib. Endpoints included overall survival (OS), progression free survival (PFS), and time to liver decompensation. Patients with undetectable HCV RNA exhibited reduced aspartate aminotransferase and alpha fetoprotein levels, as well as an attenuated proportion of aHCC at initial diagnosis but increased albumin and mean sorafenib daily dosing. Patients with undetectable HCV RNA exhibited significantly longer OS compared to patients with detectable or unknown HCV RNA, which was an independent factor of OS (HR: 0.56, 95% CI: 0.350‐0.903, P =.017). Patients with undetectable HCV RNA also presented a trend for longer PFS (HR 0.68, 95% CI: 0.46‐1.00, P =.053). The survival benefit was considered with respect to the significantly prolonged time to Child‐Pugh B scores in patients with undetectable HCV RNA (HR 0.59, 95% CI: 0.38‐0.92, P =.020). Patients with detectable HCV RNA at sorafenib initiation who further received direct acting antiviral therapy also had significantly longer OS (HR 0.11, 95% CI: 0.02‐0.81, P =.030) and PFS (HR 0.23, 95% CI: 0.06‐0.99, P =.048). In conclusion, abolishing HCV viremia preserves liver function and confers a survival benefit in advanced HCC patients on sorafenib treatment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

14. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon‐free direct antiviral agents

Author

Huang, Jee‐Fu, primary, Huang, Chung‐Feng, additional, Yeh, Ming‐Lun, additional, Dai, Chia‐Yen, additional, Hsieh, Meng‐Hsuan, additional, Yang, Jeng‐Fu, additional, Huang, Ching‐I., additional, Lin, Yi‐Hung, additional, Liang, Po‐Cheng, additional, Lin, Zu‐Yau, additional, Chen, Shinn‐Chern, additional, Yu, Ming‐Lung, additional, and Chuang, Wan‐Long, additional

Published
2017
Full Text
View/download PDF

16. Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients

Author

Huang, Jee-Fu, primary, Yeh, Ming-Lun, additional, Huang, Chung-Feng, additional, Huang, Ching-I, additional, Tsai, Pei-Chien, additional, Tai, Chi-Ming, additional, Yang, Hua-Ling, additional, Dai, Chia-Yen, additional, Hsieh, Meng-Hsuan, additional, Chen, Shinn-Chern, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2017
Full Text
View/download PDF

17. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study

Author

Yeh, Ming-Lun, primary, Huang, Ching-I., additional, Hsieh, Ming-Yen, additional, Huang, Chung-Feng, additional, Hsieh, Meng-Hsuan, additional, Huang, Jee-Fu, additional, Dai, Chia-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Yu, Ming-Lung, additional, and Chuang, Wan-Long, additional

Published
2016
Full Text
View/download PDF

18. Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients

Author

Huang, Jee-Fu, primary, Yeh, Ming-Lun, additional, Yu, Ming-Lung, additional, Huang, Chung-Feng, additional, Dai, Chia-Yen, additional, Hsieh, Ming-Yen, additional, Hsieh, Meng-Hsuan, additional, Huang, Ching-I, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Hsiao, Pi-Jung, additional, Shin, Shyi-Jang, additional, and Chuang, Wan-Long, additional

Published
2015
Full Text
View/download PDF

19. Independent and Additive Interaction Between Tumor Necrosis Factor β +252 Polymorphisms and Chronic Hepatitis B and C Virus Infection on Risk and Prognosis of Hepatocellular Carcinoma: a Case-Control Study

Author

Jeng, Jen-Eing, primary, Wu, Hui-Fang, additional, Tsai, Meng-Feng, additional, Tsai, Huey-Ru, additional, Chuang, Lea-Yea, additional, Lin, Zu-Yau, additional, Hsieh, Min-Yuh, additional, Chen, Shinn-Chern, additional, Chuang, Wan-Lung, additional, Wang, Liang-Yen, additional, Yu, Ming-Lung, additional, Dai, Chia-Yen, additional, and Tsai, Jung-Fa, additional

Published
2015
Full Text
View/download PDF

20. Impact of Chronic Hepatitis B and Hepatitis C on Adverse Hepatic Fibrosis in Hepatocellular Carcinoma Related to Betel Quid Chewing

Author

Jeng, Jen-Eing, primary, Tsai, Meng-Feng, additional, Tsai, Hey-Ru, additional, Chuang, Lea-Yea, additional, Lin, Zu-Yau, additional, Hsieh, Min-Yuh, additional, Chen, Shinn-Chern, additional, Chuang, Wan-Lung, additional, Wang, Liang-Yen, additional, Yu, Ming-Lung, additional, Dai, Chia-Yen, additional, and Tsai, Jung-Fa, additional

Published
2014
Full Text
View/download PDF

21. Independent and additive interaction between polymorphisms of tumor necrosis factor α−308 and lymphotoxin α+252 on risk of hepatocellular carcinoma related to hepatitis B

Author

Tsai, Jung‐Fa, Chen, Shinn‐Chern, Lin, Zu‐Yau, Dai, Chia‐Yen, Huang, Jee‐Fu, Yu, Min‐Lung, and Chuang, Wan‐Long

Abstract

This case–control study was aimed to assess the effect of genetic variants of tumor necrosis factor (TNF)α−308 and lymphotoxin (LT)α+252 on development of hepatitis B virus (HBV)‐related hepatocellular carcinoma (HCC). Their gene–gene interaction was also investigated. We enrolled 200 pairs of age‐ and sex‐matched patients with cirrhotic HBV‐HCC and unrelated patients with HBV‐cirrhosis alone. Polymorphisms of TNFα−308 and LTα+252 were genotyped. Synergy index was used to calculate interaction between the variant genotypes. The results indicated that the frequency distribution of the variant genotypes (TNFα−308 G/A and LTα+252 G/G) in patients with HCC were significantly higher than those in patients with cirrhosis alone. Multivariate analysis indicated that TNFα−308 G/A (odds ratio [OR], 2.34) and LTα+252 G/G (OR, 2.04) were independent risk factors for HCC. By the clinical characteristics of study population, multivariate analysis demonstrated that independent factors associated with harboring the variant genotypes included cirrhosis with Child‐Pugh C (OR = 6.47 in cases and OR = 11.56 in controls) and thrombocytopenia (OR = 8.86 in cases and OR = 7.74 in controls). Calculation of synergy index (SI) indicated that there are additive interaction between TNFα−308 G/A and LTα+252 G/G on risk of HCC (SI = 1.29). In conclusion: There are independent and additive interactions between TNFα−308 G/A and LTα+252 G/G on risk for HBV‐HCC. They correlated with advanced hepatic fibrosis and severe liver damage, which might contribute to a higher risk for HCC.

Published
2017
Full Text
View/download PDF

22. Interactive effects between Lymphotoxin α+252 polymorphism and habits of substance use on risk of hepatocellular carcinoma

Author

Tsai, Jung‐Fa, Chen, Shinn‐Chern, Lin, Zu‐Yau, Dai, Chia‐Yen, Huang, Jee‐Fu, Yu, Min‐Lung, and Chuang, Wan‐Long

Abstract

This case–control study aimed to assess the interactive effect between polymorphisms of lymphotoxin (LT) α+252 and habitual substance use on risk of hepatocellular carcinoma (HCC). We enrolled 150 pairs of sex‐ and age‐matched HCC patients and unrelated healthy controls. LTαgenotypes were detected with polymerase‐chain reaction and restrictive fragment length polymorphisms. Information about habits of substance use was obtained through personal interview. Multivariate analysis indicated that LTα+252 G/G genotypes [odds ratio (OR) = 3.36], Hepatitis B surface antigen (OR = 16.68), antibodies to hepatitis C virus (OR = 34.88) and having at least two habits of substance use (OR = 2.50) were independent risk factors for HCC. There were additive interactions among LTα+252 G/G genotype, chronic viral hepatitis, and habit of each substance use. In conclusion: There are independent and additive interactions between LTα +252 G/Ggenotype, chronic viral hepatitis, and habits of substance use on risk of HCC.

Published
2017
Full Text
View/download PDF

23. Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C

Author

Huang, Jee-Fu, primary, Huang, Chao-Kuan, additional, Yu, Ming-Lung, additional, Dai, Chia-Yen, additional, Huang, Chung-Feng, additional, Hung, Wei-Wen, additional, Yeh, Ming-Lun, additional, Hsieh, Meng-Hsuan, additional, Yang, Jeng-Fu, additional, Hsieh, Ming-Yen, additional, Lin, Zu-Yau, additional, Chen, Shinn-Chern, additional, Wu, Shun-Sheng, additional, and Chuang, Wan-Long, additional

Published
2011
Full Text
View/download PDF

24. Hepatic Steatosis and Fibrosis in Chronic Hepatitis C in Taiwan

Author

Hsieh, Meng-Hsuan, primary, Lee, Li-Po, additional, Hsieh, Ming-Yen, additional, Tsai, Kun-Bow, additional, Huang, Jee-Fu, additional, Hou, Nai-Jen, additional, Chen, Shinn-Chern, additional, Lin, Zu-Yau, additional, Hsieh, Ming-Yuh, additional, Wang, Liang-Yen, additional, Dai, Chia-Yen, additional, Chuang, Wan-Long, additional, and Yu, Ming-Lung, additional

Published
2007
Full Text
View/download PDF

26. Independent and additive interaction between polymorphisms of tumor necrosis factor α-308 and lymphotoxin α+252 on risk of hepatocellular carcinoma related to hepatitis B.

Author

Tsai JF, Chen SC, Lin ZY, Dai CY, Huang JF, Yu ML, and Chuang WL

Subjects
5' Untranslated Regions, Adult, Aged, Alleles, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular virology, Case-Control Studies, Epistasis, Genetic, Female, Gene Expression, Gene Frequency, Genetic Predisposition to Disease, Haplotypes, Hepatitis B complications, Hepatitis B pathology, Hepatitis B virology, Hepatitis B virus genetics, Hepatitis B virus isolation & purification, Humans, Liver Cirrhosis etiology, Liver Cirrhosis pathology, Liver Cirrhosis virology, Liver Neoplasms etiology, Liver Neoplasms pathology, Liver Neoplasms virology, Male, Middle Aged, Odds Ratio, Promoter Regions, Genetic, Risk Factors, Carcinoma, Hepatocellular genetics, Hepatitis B genetics, Liver Cirrhosis genetics, Liver Neoplasms genetics, Lymphotoxin-alpha genetics, Polymorphism, Single Nucleotide, Tumor Necrosis Factor-alpha genetics
Abstract

This case-control study was aimed to assess the effect of genetic variants of tumor necrosis factor (TNF) α-308 and lymphotoxin (LT) α+252 on development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Their gene-gene interaction was also investigated. We enrolled 200 pairs of age- and sex-matched patients with cirrhotic HBV-HCC and unrelated patients with HBV-cirrhosis alone. Polymorphisms of TNFα-308 and LTα+252 were genotyped. Synergy index was used to calculate interaction between the variant genotypes. The results indicated that the frequency distribution of the variant genotypes (TNFα-308 G/A and LTα+252 G/G) in patients with HCC were significantly higher than those in patients with cirrhosis alone. Multivariate analysis indicated that TNFα-308 G/A (odds ratio [OR], 2.34) and LTα+252 G/G (OR, 2.04) were independent risk factors for HCC. By the clinical characteristics of study population, multivariate analysis demonstrated that independent factors associated with harboring the variant genotypes included cirrhosis with Child-Pugh C (OR = 6.47 in cases and OR = 11.56 in controls) and thrombocytopenia (OR = 8.86 in cases and OR = 7.74 in controls). Calculation of synergy index (SI) indicated that there are additive interaction between TNFα-308 G/A and LTα+252 G/G on risk of HCC (SI = 1.29)., In Conclusion: There are independent and additive interactions between TNFα-308 G/A and LTα+252 G/G on risk for HBV-HCC. They correlated with advanced hepatic fibrosis and severe liver damage, which might contribute to a higher risk for HCC., (Copyright © 2017 Kaohsiung Medical University. Published by Elsevier Taiwan. All rights reserved.)

Published
2017
Full Text
View/download PDF

27. Independent and additive interaction between tumor necrosis factor β +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study.

Author

Jeng JE, Wu HF, Tsai MF, Tsai HR, Chuang LY, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, and Tsai JF

Subjects
Adult, Aged, Carcinoma, Hepatocellular etiology, Carcinoma, Hepatocellular mortality, Female, Genetic Predisposition to Disease, Hepacivirus immunology, Hepatitis Antibodies immunology, Hepatitis B Surface Antigens blood, Hepatitis B, Chronic blood, Hepatitis C, Chronic immunology, Humans, Liver Cirrhosis etiology, Liver Neoplasms etiology, Liver Neoplasms mortality, Male, Middle Aged, Multivariate Analysis, Polymorphism, Single Nucleotide, Prognosis, Proportional Hazards Models, Thrombocytopenia etiology, Thrombocytopenia genetics, alpha-Fetoproteins, Carcinoma, Hepatocellular genetics, Hepatitis B, Chronic complications, Hepatitis C, Chronic complications, Liver Cirrhosis genetics, Liver Neoplasms genetics, Lymphotoxin-alpha genetics
Abstract

To assess the contribution of tumor necrosis factor (TNF)β +252 polymorphisms to risk and prognosis of hepatocellular carcinoma (HCC), we enrolled 150 pairs of sex- and age-matched patients with HCC, patients with cirrhosis alone, and unrelated healthy controls. TNFβ +252 genotypes were determined by polymerase chain reaction with restriction fragment length polymorphism. Multivariate analysis indicated that TNFβ G/G genotype [odds ratio (OR), 3.64; 95%CI, 1.49-8.91], hepatitis B surface antigen (OR, 16.38; 95%CI, 8.30-32.33), and antibodies to hepatitis C virus (HCV) (OR, 39.11; 95%CI, 14.83-103.14) were independent risk factors for HCC. There was an additive interaction between TNFβ G/G genotype and chronic hepatitis B virus (HBV)/HCV infection (synergy index=1.15). Multivariate analysis indicated that factors associated with TNFβ G/G genotype included cirrhosis with Child-Pugh C (OR, 4.06; 95%CI, 1.34-12.29), thrombocytopenia (OR, 6.55; 95%CI, 1.46-29.43), and higher serum α-fetoprotein concentration (OR, 2.53; 95%CI, 1.14-5.62). Patients with TNFβ G/G genotype had poor cumulative survival (p=0.005). Cox proportional hazard model indicated that TNFβ G/G genotype was a biomarker for poor HCC survival (hazard ratio, 1.70; 95%CI, 1.07-2.69). In conclusion, there are independent and additive effects between TNFβ G/G genotype and chronic HBV/HCV infection on risk for HCC. It is a biomarker for poor HCC survival. Carriage of this genotype correlates with disease severity and advanced hepatic fibrosis, which may contribute to a higher risk and poor survival of HCC. Chronic HBV/HCV infected subjects with this genotype should receive more intensive surveillance for early detection of HCC.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results